Lawrence Tabak, DDS, PhD
Section on Biological Chemistry
Principal Deputy Director
Lab: Building 30, Room 524
NIH Office: Building 1, Room 126
Bethesda MD 20892-2290
Dr. Lawrence Tabak's laboratory studies the functions and biosynthesis of O-glycans. Mucin-glycoproteins are heavily decorated with carbohydrate side-chains, termed O-glycans, which are often clustered within repeating amino acids sequences of the protein (tandem repeats). Functionally, membrane-bound mucins are involved in signal transduction events, whereas secreted mucins contribute to the formation of extracellular matrix or to the gel-like mucus coat which envelopes mucosal surfaces of the body thereby forming the most exterior face of the innate immune system. Although it is known that O-glycans are ubiquitous among proteins, the precise nature of the “O-glycome” remains to be defined. We have approached this by both top-down and bottom-up proteomic studies as well as investigations of the substrate specificities of the multi-gene family of enzymes that are responsible for the formation of O-glycans, the UDP-GalNAc:polypeptide N-Acetylgalactosaminyltransferases (GalNAcTs).
Dr. Lawrence Tabak began serving as NIDCR acting director on January 1, 2020, following the retirement of Dr. Martha Somerman. In addition, Dr. Tabak is the principal deputy director of NIH, a position he has held since August 23, 2010; prior to that, he was acting principal deputy director of NIH from November 2008 through August 2009. Named as the director of NIDCR in September 2000, , he held that post through August 2010. Prior to joining NIH, Dr. Tabak served as the senior associate dean for research and professor of dentistry and biochemistry & biophysics in the School of Medicine and Dentistry at the University of Rochester in New York. A former NIH MERIT recipient, Dr. Tabak has received several honors and awards for his work including election to membership in the Institute of Medicine of the National Academies. He has also received teaching awards for his work with both graduate and medical students.
Revoredo L, Wang S, Bennett EP, Clausen H, Moremen KW, Jarvis DL, Ten Hagen KG, Tabak LA, Gerken TA. Mucin-type O-glycosylation is controlled by short- and long-range glycopeptide substrate recognition that varies among members of the polypeptide GalNAc transferase family. Glycobiology. 2016;26(4):360-76.
Ji S, Samara NL, Revoredo L, Zhang L, Tran DT, Muirhead K, Tabak LA, Ten Hagen KG. A molecular switch orchestrates enzyme specificity and secretory granule morphology. Nat Commun. 2018;9(1):3508.
Tian E, Wang S, Zhang L, Zhang Y, Malicdan MC, Mao Y, Christoffersen C, Tabak LA, Schjoldager KT, Ten Hagen KG. Galnt11 regulates kidney function by glycosylating the endocytosis receptor megalin to modulate ligand binding. Proc Natl Acad Sci U S A. 2019;116(50):25196-25202.
Fernandez AJ, Daniel EJP, Mahajan SP, Gray JJ, Gerken TA, Tabak LA, Samara NL. The structure of the colorectal cancer-associated enzyme GalNAc-T12 reveals how nonconserved residues dictate its function. Proc Natl Acad Sci U S A. 2019;116(41):20404-20410.
May C, Ji S, Syed ZA, Revoredo L, Daniel EJP, Gerken TA, Tabak LA, Samara NL, Ten Hagen KG. Differential splicing of the lectin domain of an O-glycosyltransferase modulates both peptide and glycopeptide preferences. J Biol Chem. 2020.
Related Scientific Focus Areas
Molecular Biology and Biochemistry
This page was last updated on January 28th, 2020